sq-11725 has been researched along with digoxin in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (22.22) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 8 (44.44) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Johans, C; Kinnunen, PK; Söderlund, T; Suomalainen, P | 1 |
| Artursson, P; Bergström, CA; Matsson, P; Nagahara, N; Norinder, U; Tavelin, S | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Avdeef, A; Tam, KY | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Brewington, J; Gore, R; Olukotun, AY; Zoble, RG | 1 |
| Hoff, PT; Kitzen, JM; Lucchesi, BR; Lynch, JJ | 1 |
| Kuo, CS; Paciotti, MV; Reddy, CP | 1 |
| Chadda, KD; DiBianco, R; Donohue, DJ; Freitag, JA; Larca, LJ; Lindgren, KM; Morganroth, J; Olukotun, AY; Ronan, JA | 1 |
| Belli, G; Brambilla, A; Capponi, G; De Simone, L; Favilli, S; Giovannini, M; Porcedda, G; Remaschi, G; Vannuccini, F | 1 |
2 trial(s) available for sq-11725 and digoxin
| Article | Year |
|---|---|
Comparative effects of nadolol-digoxin combination therapy and digoxin monotherapy for chronic atrial fibrillation.
Topics: Adult; Aged; Atrial Fibrillation; Chronic Disease; Circadian Rhythm; Clinical Trials as Topic; Digoxin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Exercise Test; Female; Heart Rate; Humans; Male; Middle Aged; Nadolol; Random Allocation | 1987 |
Effects of nadolol on the spontaneous and exercise-provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atrial Fibrillation; Clinical Trials as Topic; Digoxin; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Heart Rate; Humans; Male; Middle Aged; Nadolol; Physical Exertion; Propanolamines; Random Allocation; Time Factors | 1984 |
16 other study(ies) available for sq-11725 and digoxin
| Article | Year |
|---|---|
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
Topics: Blood-Brain Barrier; Lipid Bilayers; Micelles; Permeability; Pharmaceutical Preparations; Structure-Activity Relationship; Surface Properties | 2004 |
Exploring the role of different drug transport routes in permeability screening.
Topics: Administration, Oral; Biological Transport; Caco-2 Cells; Cell Line; Humans; Intestinal Absorption; Intestinal Mucosa; Intestine, Small; Membranes, Artificial; Models, Biological; Molecular Conformation; Monte Carlo Method; Permeability; Pharmaceutical Preparations; Pharmacokinetics | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Reduction in digitalis-associated postinfarction mortality with nadolol in conscious dogs.
Topics: Animals; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Digitalis; Digoxin; Dogs; Drug Administration Schedule; Electric Stimulation; Electrocardiography; Electrophysiology; Myocardial Infarction; Nadolol; Plants, Medicinal; Plants, Toxic | 1988 |
Asystole during treatment with amiodarone in a patient with persistent atrial tachycardia.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzofurans; Digoxin; Drug Therapy, Combination; Electrocardiography; Female; Heart Arrest; Heart Atria; Heart Rate; Humans; Nadolol; Propanolamines; Tachycardia | 1985 |
Supraventricular tachycardias in the first year of life: what is the best pharmacological treatment? 24 years of experience in a single centre.
Topics: Action Potentials; Adrenergic beta-Antagonists; Age Factors; Anti-Arrhythmia Agents; Digoxin; Drug Therapy, Combination; Female; Flecainide; Heart Rate; Humans; Infant; Infant, Newborn; Male; Nadolol; Recurrence; Retrospective Studies; Sotalol; Tachycardia, Supraventricular; Time Factors; Treatment Outcome; Voltage-Gated Sodium Channel Blockers | 2021 |